NEW YORK, Dec. 27, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the American Depositary Shares (“ADSs”) of Teva Pharmaceutical Industries Limited (NYSE:TEVA) between February 10, 2015 and November 3, 2016, both dates inclusive (the “Class Period”) of the important January 5, 2017 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks recovery of investor losses. Investors with losses in excess of $1 million are encouraged to contact the firm about the lead plaintiff deadline.
To join the Teva class action, go to http://www.rosenlegal.com/cases-979.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice (“DOJ”) and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Teva by the end of 2016 for suspected price collusion; (3) in turn, Teva lacked effective internal controls over financial reporting; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2017. If you wish to join the litigation, go to: http://www.rosenlegal.com/cases-979.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 



